Neil R. Aggarwal, L. Beaty, Tellen D. Bennett, Lindsey E. Fish, Jason R. Jacobs, D. Mayer, Kyle C. Molina, Jennifer L. Peers, Douglas B. Richardson, S. Russell, Alejandro Varela, Brandon J. Webb, Matthew K. Wynia, Mengli Xiao, N. Carlson, A. Ginde
{"title":"美国三个医疗系统在BQ.1、BQ.1.1.和XBB.1.5占主导地位的奥米克变体期间在COVID-19门诊患者中实际使用nirmatrelvir-ritonavir的情况:一项回顾性队列研究","authors":"Neil R. Aggarwal, L. Beaty, Tellen D. Bennett, Lindsey E. Fish, Jason R. Jacobs, D. Mayer, Kyle C. Molina, Jennifer L. Peers, Douglas B. Richardson, S. Russell, Alejandro Varela, Brandon J. Webb, Matthew K. Wynia, Mengli Xiao, N. Carlson, A. Ginde","doi":"10.1016/j.lana.2024.100693","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":516575,"journal":{"name":"The Lancet Regional Health - Americas","volume":"380 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Real-world use of nirmatrelvir-ritonavir in COVID-19 outpatients during BQ.1, BQ.1.1., and XBB.1.5 predominant omicron variants in three U.S. health systems: a retrospective cohort study\",\"authors\":\"Neil R. Aggarwal, L. Beaty, Tellen D. Bennett, Lindsey E. Fish, Jason R. Jacobs, D. Mayer, Kyle C. Molina, Jennifer L. Peers, Douglas B. Richardson, S. Russell, Alejandro Varela, Brandon J. Webb, Matthew K. Wynia, Mengli Xiao, N. Carlson, A. Ginde\",\"doi\":\"10.1016/j.lana.2024.100693\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":516575,\"journal\":{\"name\":\"The Lancet Regional Health - Americas\",\"volume\":\"380 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Lancet Regional Health - Americas\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.lana.2024.100693\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet Regional Health - Americas","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.lana.2024.100693","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Real-world use of nirmatrelvir-ritonavir in COVID-19 outpatients during BQ.1, BQ.1.1., and XBB.1.5 predominant omicron variants in three U.S. health systems: a retrospective cohort study